New, tolerable γ-secretase inhibitor takes desmoid down a notch.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25336699.
- Also identified by DOI 10.1158/1078-0432.CCR-14-1660 and PMC identifier 4306586.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A phase I trial of PF-03084014, an oral reversible γ-secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma.
Medical subject headings
- Amyloid Precursor Protein Secretases
- Enzyme Inhibitors
- Neoplasms
- Tetrahydronaphthalenes
- Valine